Eli Lilly & Co. v. Teva Parenteral Medicines, Inc.

567 F. App'x 967
CourtCourt of Appeals for the Federal Circuit
DecidedJuly 25, 2014
DocketNo. 2014-1455
StatusPublished

This text of 567 F. App'x 967 (Eli Lilly & Co. v. Teva Parenteral Medicines, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., 567 F. App'x 967 (Fed. Cir. 2014).

Opinion

ON MOTION

ORDER

BRYSON, Circuit Judge.

The parties jointly move to remand this appeal so that they can litigate the issue of infringement in light of the United States Supreme Court’s recent decision in Limelight Networks, Inc. v. Akamai Technologies, Inc., — U.S. -, 134 S.Ct. 2111, 189 L.Ed.2d 52 (2014). In the district court, the parties jointly stipulated to induced infringement and proceeded to trial only on validity. As part of that stipulation, however, appellants reserved the right to litigate infringement if the Supreme Court granted the then-pending petition for writ of certiorari in Akamai and reversed or vacated this court’s decision.

Accordingly,

It Is ORdered That:

(1) The motion is granted. This case is remanded for further proceedings consistent with this order.

(2) Each side shall bear its own costs.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Limelight Networks, Inc. v. Akamai Technologies, Inc.
134 S. Ct. 2111 (Supreme Court, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
567 F. App'x 967, Counsel Stack Legal Research, https://law.counselstack.com/opinion/eli-lilly-co-v-teva-parenteral-medicines-inc-cafc-2014.